Headache News and Research

Latest Headache News and Research

SAGE forges agreement with the International Headache Society

SAGE, the world's leading independent academic and professional publisher is delighted to announce a new agreement with the International Headache Society (IHS) to publish their official journal, Cephalalgia.

2 Sep 2009

Children suffering from chronic headache may outgrow the condition

Most children who suffer from chronic daily headache may outgrow the disabling condition, according to research published in the July 15, 2009, online issue of NeurologyÂ®, the medical journal of the American Academy of Neurology. Nearly 1.5 percent of middle school children are affected by chronic daily headache, which includes chronic migraines and tension-type headaches.

1 Sep 2009

Rite Aid pharmacies to offer regular seasonal flu shots throughout the flu season

Many Rite Aid pharmacists have already been giving regular seasonal flu shots following the Centers for Disease Control and Prevention (CDC) advice that anyone who wishes to reduce the risk of getting the regular seasonal flu get a flu shot as soon as they are available.

31 Aug 2009

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.

31 Aug 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

Sagent Pharmaceuticals adds fluconazole injection to its line of premixed bags

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched fluconazole injection in premix bags. IMS Health estimates that 2008 U.S. sales of fluconazole injection approximated $18 million. Sagent will begin marketing and shipping fluconazole bags immediately.

28 Aug 2009

Forest Laboratories announces phase 3 trial results for roflumilast

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.

28 Aug 2009

Abortion questions continue in health reform debate

The Wall Street Journal reports: "Anti-abortion groups are gearing up for a battle in the fall over health-care legislation, another headache for Democrats who already face concerns about the measure's cost and reach. Most versions of the Democratic health plan would create subsidies for lower-income people to buy private health insurance.

27 Aug 2009

First Edition: August 27, 2009

Today's news: Speculation begins regarding the impact Sen. Kennedy's death will have on the health reform debate and the Democrat's prospects for success.

27 Aug 2009

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

Bristol-Myers Squibb Company announced today that clinical data added to the labeling for ORENCIA (abatacept) support use of ORENCIA for patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

27 Aug 2009

Alexza completes acquisition of Symphony Allegro after sharholders' approval

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that during a special meeting of stockholders held today, its stockholders approved the proposal to issue shares of the Company's common stock and warrants to purchase shares of the Company's common stock to Symphony Capital Partners, LP and their co-investors. Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, and as a result, Alexza reacquired all rights to AZ-004, AZ-104 and AZ-002.

27 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

Nuvilex launches web site for marketing Last Shot Hangover Remedy

Nuvilex, Inc. (OTC Bulletin Board: NVLX), announces today the launch of its Last Shot Hangover Remedy(TM) ("Last Shot") web site at www.mylastshot.com. The newly released web site offers Nuvilex' customers product and use information, user testimonials, lists upcoming events, and fan page links to Facebook, Twitter, and YouTube social networking sites.

26 Aug 2009

Study reveals high levels of ergothioneine in RBCs of women with pre-eclampsia

A chemical compound found in unpasteurised food has been detected in unusually high levels in the red blood cells of pregnant women with the condition pre-eclampsia.

26 Aug 2009

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has accepted for filing and designated for Priority Review the Company’s New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE). Additionally, the FDA has informed the Company of its plan to schedule an Advisory Committee meeting in late February 2010 to discuss the application.

25 Aug 2009

Concussions could result in permanent brain impairment

Concussions, whether from an accident, sporting event, or combat, can lead to permanent loss of higher level mental processes. Scientists have debated for centuries whether concussions involve structural damage to brain tissue or whether physiological changes that merely impair the way brain cells function, explain this loss.

24 Aug 2009

Retigabine's Phase IIa clinical trial preliminary results announced

Valeant Pharmaceuticals International today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles.

24 Aug 2009

Emergency contraceptive tablet to help prevent an unintended pregnancy

There is good news for college students as they head back to campus this fall. A new emergency contraceptive, Plan B® One-Step (levonorgestrel) tablet, 1.5 mg, is now available at the local pharmacy for all students 17 and older.

24 Aug 2009

FDA issues complete response letter regarding the NDA for carisbamate

The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for carisbamate, an anti-epileptic drug in development, announced Ortho-McNeil-Janssen Pharmaceuticals, Inc.

23 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009